Rating Change
Morgan Stanley reiterated its Overweight rating on Biohaven Ltd. (NYSE:BHVN) on August 12, 2026.
Morgan Stanley reiterated its Overweight rating on Biohaven Ltd. (NYSE:BHVN) on August 12, 2026.

At publication ·
Biohaven Ltd. (NYSE:BHVN) · reiterate
At a glance
Morgan Stanley reiterated its Overweight rating on Biohaven Ltd. (NYSE:BHVN) on August 12, 2026.
Biohaven Ltd. operates in the Healthcare sector. The stock currently trades at $14.39 with a market capitalization of $1.2B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biohaven Ltd.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 7 Buy, 2 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 11, 2026 | RBC Capital | Outperform | N/A |
| Jun 29, 2026 | B of A Securities | Underperform | N/A |
| May 26, 2026 | HC Wainwright & Co. | Neutral | N/A |
| May 13, 2026 | Morgan Stanley | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View BHVN Stock Page
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Biohaven Ltd. (NYSE:BHVN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BHVN forecast page.
Current market data
NYSE · BHVN
$12.71
Down: -$0.08 · -0.63%
Live quote updated
Keep reading